BACKGROUND: A Phase II trial was developed to determine the efficacy and toxicity of intravenous vinorelbine, a semi-synthetic vinca alkaloid, in children, adolescent, and young adults with recurrent or refractory solid malignancies. PROCEDURES: Fifty patients were enrolled among three strata: soft tissue sarcomas [rhabdomyosarcoma (RMS), non-rhabdomyosarcoma, primitive neuroepithelial tumor] (20 patients); brain tumors [astrocytoma (4 patients), medulloblastoma (2 patients), other (16 patients)] (22 patients); neuroblastoma (8 patients). Vinorelbine was given weekly for 6 consecutive weeks during an 8-week interval. The response rate and toxicity profile was assessed. RESULTS: Among the first 35 patients treated at 33.75 mg/m(2)/dose, 25 experienced grades 3-4 neutropenia (75%). The dose was decreased to 30 mg/m(2)/dose in the remaining 15 patients. The median age was 10 years (range, 1-25). Four responses (one complete, three partial) occurred within the soft tissue sarcoma strata (all with RMS) and two occurred in the brain tumor group (medulloblastoma and astrocytoma). The most common toxicities were hematological and neurological. CONCLUSION: Vinorelbine at dose of 30 mg/m(2) can be safely administered to children with recurrent or refractory solid malignancies. The study design identified vinorelbine to be active in the sarcoma category, with a response rate of 36% (4/11) among RMS patients.
BACKGROUND: A Phase II trial was developed to determine the efficacy and toxicity of intravenous vinorelbine, a semi-synthetic vinca alkaloid, in children, adolescent, and young adults with recurrent or refractory solid malignancies. PROCEDURES: Fifty patients were enrolled among three strata: soft tissue sarcomas [rhabdomyosarcoma (RMS), non-rhabdomyosarcoma, primitive neuroepithelial tumor] (20 patients); brain tumors [astrocytoma (4 patients), medulloblastoma (2 patients), other (16 patients)] (22 patients); neuroblastoma (8 patients). Vinorelbine was given weekly for 6 consecutive weeks during an 8-week interval. The response rate and toxicity profile was assessed. RESULTS: Among the first 35 patients treated at 33.75 mg/m(2)/dose, 25 experienced grades 3-4 neutropenia (75%). The dose was decreased to 30 mg/m(2)/dose in the remaining 15 patients. The median age was 10 years (range, 1-25). Four responses (one complete, three partial) occurred within the soft tissue sarcoma strata (all with RMS) and two occurred in the brain tumor group (medulloblastoma and astrocytoma). The most common toxicities were hematological and neurological. CONCLUSION:Vinorelbine at dose of 30 mg/m(2) can be safely administered to children with recurrent or refractory solid malignancies. The study design identified vinorelbine to be active in the sarcoma category, with a response rate of 36% (4/11) among RMS patients.
Authors: S Palmeri; V Leonardi; V Gebbia; M T De Bella; F Ferraù; G Faillú; M Spatafora; R Valenza; G Di Vita; S Vitello; R Carroccio; G Sciortino; M Vaglica; V Accurso; B Agostara; G Licata Journal: Lung Cancer Date: 2001-10 Impact factor: 5.705
Authors: Mary Johansen; John Kuttesch; W Archie Bleyer; Mark Krailo; Matthew Ames; Timothy Madden Journal: Clin Cancer Res Date: 2006-01-15 Impact factor: 12.531
Authors: David Stuckler; Jyotsana Singhal; Sharad S Singhal; Sushma Yadav; Yogesh C Awasthi; Sanjay Awasthi Journal: Cancer Res Date: 2005-02-01 Impact factor: 12.701
Authors: M L Hanley; G B Elion; O M Colvin; P L Modrich; S Keir; D J Adams; D D Bigner; H S Friedman Journal: Cancer Chemother Pharmacol Date: 1998 Impact factor: 3.333
Authors: A Fellous; R Ohayon; T Vacassin; S Binet; H Lataste; A Krikorian; J P Couzinier; V Meininger Journal: Semin Oncol Date: 1989-04 Impact factor: 4.929
Authors: Eric A Lee; Michael K Keutmann; Melissa L Dowling; Eleanor Harris; Gordon Chan; Gary D Kao Journal: Mol Cancer Ther Date: 2004-06 Impact factor: 6.261
Authors: Andrea Maria Cappellano; Antonio Sergio Petrilli; Nasjla Saba da Silva; Frederico Adolfo Silva; Priscila Mendes Paiva; Sergio Cavalheiro; Eric Bouffet Journal: J Neurooncol Date: 2014-11-01 Impact factor: 4.130
Authors: Leo Mascarenhas; Yueh-Yun Chi; Pooja Hingorani; James R Anderson; Elizabeth R Lyden; David A Rodeberg; Daniel J Indelicato; Simon C Kao; Roshni Dasgupta; Sheri L Spunt; William H Meyer; Douglas S Hawkins Journal: J Clin Oncol Date: 2019-09-12 Impact factor: 44.544
Authors: Josephine H Haduong; Christine M Heske; Wendy Allen-Rhoades; Wei Xue; Lisa A Teot; David A Rodeberg; Sarah S Donaldson; Aaron Weiss; Douglas S Hawkins; Rajkumar Venkatramani Journal: Pediatr Blood Cancer Date: 2022-02-07 Impact factor: 3.167
Authors: E Anders Kolb; Richard Gorlick; C Patrick Reynolds; Min H Kang; Hernan Carol; Richard Lock; Stephen T Keir; John M Maris; Catherine A Billups; Christopher Desjardins; Raushan T Kurmasheva; Peter J Houghton; Malcolm A Smith Journal: Pediatr Blood Cancer Date: 2013-03-28 Impact factor: 3.167
Authors: Tanya M Trippett; Cindy L Schwartz; R Paul Guillerman; Alan S Gamis; Sharon Gardner; Shirley Hogan; Wendy B London; Lu Chen; Pedro de Alarcon Journal: Pediatr Blood Cancer Date: 2014-10-12 Impact factor: 3.167